Chinese Scientists Working On Robot That Could Give Birth To Human Baby, Prototype To Launch In 2026
The fetus is expected to grow inside an artificial womb and receive nutrients through a tube. However, the scientists haven't revealed the specifics on exactly how the egg and sperm will be fertilised.
The robot is being developed by Guangzhou-based Kaiwa Technology, led by Dr Zhang Qifeng, who is a scientist from Nanyang Technological University in Singapore.
If successful, the technology could potentially assist infertile couples or individuals who prefer not to undergo biological pregnancy.
Dr Zhang has claimed the technology is already in a "mature stage". As quoted by the media outlet, he added, "Now it needs to be implanted in the robot's abdomen so that a real person and the robot can interact to achieve pregnancy, allowing the fetus to grow inside."
A prototype of the robot is expected to be launched in 2026, with an estimated cost of around 100,000 yuan (approximately $14,000 USD).
The technology has sparked debate about ethical implications, including concerns about fetal-maternal bonding, sourcing of eggs and sperm, and psychological impact on the child.
Meanwhile, the technology is expected to revolutionise reproductive science and provide new options for individuals facing infertility challenges, which affects approximately 15 per cent of couples globally.
The concept builds on existing artificial womb research, including a 2017 experiment where premature lambs were grown in a "biobag" filled with synthetic amniotic fluid.
As per the report, Dr Zhang's team is engaging with Guangdong Province authorities on policy and legislation to address legal and ethical questions surrounding the technology.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
22 minutes ago
- Business Standard
Dixon Technologies stock jumps 4% on ₹370-cr JV with China's HKC Overseas
Dixon Technologies share price today: Shares of domestic electronics manufacturer Dixon Technologies surged over 4 per cent to hit an intraday high of ₹16,912 after the company formed a ₹370 crore joint venture with China's HKC Overseas. At 01:10 AM, Dixon's share price was trading 3.65 per cent higher at ₹16,782 per share on the NSE. In comparison, NSE Nifty50 was up 1.16 per cent at 24,916.7 levels. The market capitalisation of the company stood at ₹1.01 trillion. The stock has recovered 36.7 per cent from the 52-week low of ₹11,840 touched on August 14, 2024. CATCH STOCK MARKET LATEST UPDATES TODAY LIVE Why were Dixon Technologies shares rising? The Dixon Technologies-HKC Overseas joint venture (JV) is for manufacturing and selling of LCD and TFT-LCD modules that are used in electronic devices like TV, mobile phones, etc, for display, according to an exchange filing. "Dixon Technologies (India) has entered into a Term Sheet with HKC Corporation to form a joint venture for manufacturing of Liquid Crystal Modules, thin film transistor liquid crystal display modules, assembly of end products such as smartphones, TVs, monitors and auto displays and selling HKC-branded end products in India," the company said. HKC Overseas will acquire a 26 per cent stake in Dixon Display Technologies (DDTPL) for USD 10.998 million, and Dixon will acquire a 74 per cent stake in the JV for USD 31.3 million in two tranches. Last month, Dixon had announced a JV with Chinese electronic component maker Chongqing Yuhai Precision Manufacturing Co. and the Indian arm of Kunshan Q Technology for manufacturing and sales of electronic components used in electronic devices like mobile phones and laptops, among others. ALSO READ | Dixon Technologies Q1 results Dixon Technologies posted a strong June 2025 quarter (Q1FY26) performance, with robust performance across metrics on the back of mobile and EMS segments. The company reported revenue, Ebitda, and PAT growth of 95 per cent, 95 per cent, and 68 per cent, respectively, on a yearly basis. Brokerage firm Motilal Oswal has maintained a 'Buy' rating with a revised target price of ₹22,100 (₹20,500 earlier) based on DCF valuation. Emkay Global has also maintained a 'Buy' rating with a target price of ₹19,000. On the other hand, Nuvama Institutional Equities maintained a 'Hold' rating with a June 2026 target price of ₹16,100, citing fair valuation. About Dixon Technologies Founded in 1993, Dixon Technologies is an electronic manufacturing services (EMS) provider in India. It offers design-focused solutions across consumer durables, home appliances, lighting, mobile phones, and security devices. It also provides repair and refurbishment services for set-top boxes, mobile phones, and LED TV panels. Dixon operates across multiple divisions, including consumer electronics, lighting, mobile phones, security surveillance, medical electronics, and IT hardware. The company operates over 17 manufacturing units across India and serves both domestic and global clients.
India Today
22 minutes ago
- India Today
New health guidelines for high blood pressure: Don't ignore even mild high BP
High blood pressure, often called the 'silent killer,' is no longer just a Western health problem. In India, nearly 20 crore individuals are estimated to have hypertension, and the numbers are rising sharply in cities and smaller towns alike. It is now a leading cause of heart attacks, strokes, kidney failure, and even dementia.A new joint guideline from the American Heart Association (AHA) and the American College of Cardiology (ACC) is calling for earlier action through prevention, early treatment, and more personalised these guidelines are US-based, they carry lessons that are just as urgent for India. It says that high blood pressure should be treated earlier, not just with medicines, but also with healthy lifestyle changes. It stresses the need to carefully monitor blood pressure before, during and after pregnancy, and recommends using a new tool called the PREVENT risk calculator to check a person's chances of heart disease. Moderating alcohol intake is also one of the key ways to reduce high blood pressure, as per the new EARLY ACTION MATTERSHigh blood pressure doesn't always show symptoms until it has already caused serious damage. It is the pressure of the blood flow against the arteries is consistently can silently weaken blood vessels, strain the heart, and even harm the brain. New research highlighted in the guideline shows that hypertension can accelerate memory problems and increase the risk of dementia, a concern for India as life expectancy rises and cases of Alzheimer's disease grow.'High blood pressure is the most common and most modifiable risk factor for heart disease,' said Dr. Daniel W. Jones, chair of the guideline writing committee. Early diagnosis and treatment, he explained, not only prevent heart attacks and strokes but also protect long-term brain CHANGES AS THE FIRST TREATMENTFor most Indians, lifestyle is both the problem and the solution. Urban diets high in salt, processed foods, and fried snacks, combined with sedentary jobs and high stress, are fuelling the hypertension guideline reaffirms that healthy lifestyle habits such as cutting down on salt (a major challenge in Indian cooking and packaged foods), eating more fruits, vegetables and whole grains, exercising regularly, maintaining a healthy weight, and managing stress, remain the first line of alcohol, moderation is key. Stress management, whether through yoga, meditation, or simple breathing techniques, has particular resonance in India, where traditional practices can be powerful TOOL FOR PERSONALISED CAREThe new guideline recommends use of the PREVENT risk calculator, which helps doctors estimate an individual's 10- and 30-year risk of heart disease by considering factors like blood pressure, cholesterol, diabetes, and even socioeconomic not yet widely used in India, such tools highlight the importance of tailoring treatment to the person rather than following a one-size-fits-all India, where access to advanced tests is often limited, home blood pressure monitoring can also be a practical and cost-effective way to keep track of health between doctor WHEN NEEDEDWhile lifestyle remains central, medication is often necessary, especially when blood pressure remains high. The guideline suggests starting treatment earlier and, for those with very high readings (140/90 mm Hg or above), using two medicines together for faster used to begin medication mostly when people reached stage 2 hypertension (blood pressure of 140/90 mm Hg or higher). But the new guideline says treatment should start earlier, even at stage 1 hypertension (130–139/80–89 mm Hg), especially if a person has other risks like diabetes, kidney disease, or a family history of heart idea is that bringing blood pressure under control sooner, with lifestyle changes and medicines when needed, can prevent serious complications like heart attack, stroke, and dementia later in blood pressure: less than 120/80 mm Hg. This is where you want to blood pressure: between 120–129 (top number) and less than 80 (bottom number). This is a warning zone — not yet high blood pressure, but a signal to make lifestyle 1 hypertension: between 130–139 (top number) or 80–89 (bottom number). At this stage, doctors may recommend lifestyle changes and, if other health risks are present, starting 2 hypertension: 140/90 mm Hg or higher. This is more serious and usually requires medication along with lifestyle changes to bring numbers India, common medications like ACE inhibitors, ARBs, calcium channel blockers and diuretics are widely available and effective. For those with obesity and type 2 diabetes, both rising in the country, newer therapies such as GLP-1 drugs may offer added benefits in the ON WOMEN AND PREGNANCYThe guidelines also highlight high blood pressure in pregnancy, a serious concern in India where maternal health remains a challenge. Conditions like preeclampsia can threaten both mother and child and raise a woman's long-term risk of heart recommend close monitoring of blood pressure during and after pregnancy, timely treatment, and in some cases, low-dose aspirin to reduce risk. Postpartum follow-up is equally crucial, since blood pressure problems can persist or develop after deliveryAs Dr. Jones summed up, 'Prevention, early detection and management of high blood pressure are critical to long-term heart and brain health, which means longer, healthier lives.'advertisementFor India, this advice could not be more timely.- Ends
Business Standard
39 minutes ago
- Business Standard
KPL receives nod to sell its anti-cancer drug Bleomycin 15 IU in Mexico
Kwality Pharmaceutical has received registration for Bleomycin 15 IU in Mexico for sale and distribution. Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The company said, "This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally." The projected business potential is around 1 million USD in the first year, and supplies will commence before the end of Q2FY26
